Table 1. Baseline variables between normouricemic group and hyperuricemic group.
| Variables | Normuricemia (n=698) | Hyperuricemia (n=307) | P value |
|---|---|---|---|
| Demographic variables | |||
| Age, year | 61.09±11.89 | 63.49±13.18 | 0.006 |
| Age ≥75 years, n (%) | 99 (14.18) | 76 (24.76) | <0.0001 |
| Female, n (%) | 91 (13.04) | 65 (21.17) | 0.001 |
| Weight, kg | 64.58±10.71 | 65.19±11.54 | 0.4217 |
| Hypertension, n (%) | 322 (46.2) | 184 (59.93) | <0.0001 |
| Hypotension, n (%) | 23 (4.30) | 19 (8.88) | 0.014 |
| CKD, n (%) | 202 (29.71) | 159 (53.18) | <0.0001 |
| Hyperlipidemia, n (%) | 103 (14.76) | 50 (16.29) | 0.5340 |
| DM, n (%) | 143 (20.49) | 69 (22.48) | 0.477 |
| LVEF ≥40, %, n (%) | 575 (89.56) | 244 (85.01) | 0.047 |
| Examination | |||
| Uric acid, umol/L | 308.4±62.72 | 502.4±99.83 | <0.0001 |
| Albuminemia, g/L | 33.05±4.71 | 33.15±4.65 | 0.79 |
| LDL-C, mmol/L | 2.99±1.06 | 2.92±1.03 | 0.42 |
| Total cholesterol, mmol/L | 4.62±1.21 | 4.62±1.28 | 0.9491 |
| HbA1c (%) | 6.61±1.56 | 6.55±1.32 | 0.63 |
| Medication therapy | |||
| Beta-blocker, n (%) | 580 (83.09) | 245 (79.80) | 0.210 |
| ACEI/ARB, n (%) | 629 (90.24) | 271 (88.27) | 0.3452 |
| Statin, n (%) | 691 (99.0) | 301 (98.05) | 0.2188 |
| Procedure characteristics | |||
| CABG, n (%) | 1 (0.14) | 1 (0.33) | 0.5499 |
| Lesion length, mm | 2.14±0.95 | 2.21±1.08 | 0.4446 |
CKD, chronic kidney disease; DM, diabetes mellitus; LVEF, left ventricular ejection fraction; LDL-C, low-density lipoprotein cholesterol; ACEI/ARB, angiotensin-converting enzyme inhibitors/angiotensin receptor blocker; CABG, coronary artery bypass grafting.